RV6 Panoramica delle azioni Charles River Laboratories International, Inc. Maggiori dettagli
Premi Analisi del rischio Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
Charles River Laboratories International, Inc. Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Charles River Laboratories International Prezzi storici delle azioni Prezzo attuale dell'azione US$177.75 Massimo di 52 settimane US$251.80 Minimo di 52 settimane US$163.85 Beta 1.38 Variazione di 1 mese -5.60% Variazione a 3 mesi 0.85% Variazione di 1 anno -16.98% Variazione a 3 anni -45.81% Variazione a 5 anni 31.67% Variazione dall'IPO 559.55%
Notizie e aggiornamenti recenti
Independent Director recently sold €1.5m worth of stock Nov 13
Charles River Laboratories International, Inc. Revises Earnings Guidance for Year 2024 Nov 07
Third quarter 2024 earnings released: EPS: US$1.36 (vs US$1.70 in 3Q 2023) Nov 07 Charles River Laboratories International, Inc. Launches New Retrogenix Non-Human Protein Library
Now 20% undervalued after recent price drop Sep 23
Now 20% undervalued after recent price drop Aug 13 Vedi altri aggiornamenti
Independent Director recently sold €1.5m worth of stock Nov 13
Charles River Laboratories International, Inc. Revises Earnings Guidance for Year 2024 Nov 07
Third quarter 2024 earnings released: EPS: US$1.36 (vs US$1.70 in 3Q 2023) Nov 07 Charles River Laboratories International, Inc. Launches New Retrogenix Non-Human Protein Library
Now 20% undervalued after recent price drop Sep 23
Now 20% undervalued after recent price drop Aug 13
Second quarter 2024 earnings released: EPS: US$1.75 (vs US$1.89 in 2Q 2023) Aug 08 Charles River Laboratories International, Inc. (NYSE:CRL) announces an Equity Buyback for $1,000 million worth of its shares.
Now 21% undervalued after recent price drop Jul 19
Charles River Laboratories International, Inc. to Report Q2, 2024 Results on Aug 07, 2024 Jul 17
Charles River Laboratories International, Inc. Launches Viral Vector Tech Transfer Program to Safeguard Gene Therapy Development May 31 Charles River Laboratories International, Inc. Reports Impairment Charges for the First Quarter Ended March 30, 2024 May 12
Charles River Laboratories International, Inc. Reports Unaudited Consolidated Impairment Charges for the First Quarter Ended March 30, 2024
First quarter 2024 earnings released: EPS: US$1.31 (vs US$2.02 in 1Q 2023) May 09
Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing Apr 16
Charles River Laboratories International, Inc. to Report Q1, 2024 Results on May 09, 2024 Apr 13
Charles River Laboratories International, Inc. and Deciphex Limited Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology Apr 12
Charles River Laboratories International, Inc., Annual General Meeting, May 08, 2024 Mar 30
Insider recently sold €1.2m worth of stock Mar 04
Insider recently sold €930k worth of stock Feb 26
Charles River Laboratories International, Inc. (NYSE:CRL) acquired additional 41% stake in Noveprim Limited for approximately $210 million. Feb 15
Full year 2023 earnings released: EPS: US$9.27 (vs US$9.57 in FY 2022) Feb 15
Charles River Laboratories International, Inc. Introduces First Rapid Animal-Free Bacterial Endotoxin Test Jan 29
Charles River Laboratories International, Inc. Appoints Reshema Kemps-Polanco to Board of Directors Jan 25
Charles River Laboratories International, Inc. to Report Q4, 2023 Results on Feb 14, 2024 Jan 24 Charles River Launches Rep/Cap Plasmids to Streamline Adeno-Associated Viral Vector Manufacturing
Now 21% undervalued Jan 17
Charles River Laboratories International, Inc. Introduces Cliniprime Cryopreserved Leukopaks, Expanding Suite of Gmp-Compliant Cellular Products Nov 18
Chairman recently bought €922k worth of stock Nov 16
Third quarter 2023 earnings released: EPS: US$1.70 (vs US$1.90 in 3Q 2022) Nov 09
Charles River Laboratories International, Inc. Provides Earnings Guidance for the Full Year 2023 Nov 09
Insufficient new directors Nov 01
Charles River Laboratories International, Inc. to Report Q3, 2023 Results on Nov 08, 2023 Oct 17
Charles River Laboratories International, Inc. Unveils Lentivation Platform to Expedite Lvv-Based Gene Therapy Manufacturing Sep 27
Charles River Laboratories International, Inc. Reaffirms Earnings Guidance for the Year 2023 and Provides Revenue Guidance for the Year 2024 Sep 23
Insider recently sold €1.1m worth of stock Aug 16 Charles River Laboratories International, Inc. Provides Earnings Guidance for the Full Year 2023 Aug 10
Second quarter 2023 earnings released: EPS: US$1.89 (vs US$2.15 in 2Q 2022) Aug 10
Now 20% undervalued Aug 04
Now 21% undervalued Jul 19
Glancy Prongay & Murray LLP Announces Investors with Substantial Losses Have Opportunity to Lead the Securities Fraud Class Action Lawsuit Against Charles River Laboratories International, Inc Jun 24
Charles River Laboratories International, Inc. Launches Off-The-Shelf Lentiviral Vector Packaging Plasmids Jun 14
Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Charles River Laboratories International, Inc May 20
Now 18% undervalued after recent price drop May 16
Insider recently sold €170k worth of stock May 16
First quarter 2023 earnings released: EPS: US$2.02 (vs US$1.84 in 1Q 2022) May 12
Charles River Laboratories International, Inc. Revises Earnings Guidance for the Fiscal Year 2023 May 12
Investor sentiment deteriorates as stock falls 16% Mar 13
Independent Director recently bought €365k worth of stock Mar 01
Full year 2022 earnings released: EPS: US$9.57 (vs US$7.77 in FY 2021) Feb 23
Charles River Laboratories Launches Novel IgY-based ELISA Kit for the Detection and Quantitation of Residual Host Cell Protein Feb 14
Charles River Laboratories International, Inc. to Report Q4, 2022 Results on Feb 22, 2023 Feb 10
Charles River Laboratories International, Inc. (NYSE : CRL) acquired the remaining 80% stake in Samdi Tech, Inc. for $50 million. Jan 31
Charles River Laboratories International, Inc. Announces the Launch of Their New CliniPrimeTM Suite of Good Manufacturing Practice Compliant Cellular Starting Materials Jan 17
Charles River Establishes eXpDNA Plasmid Manufacturing Platform to Expedite DNA Programs Jan 13
Arlington Management Employees, LLC acquired Avian Vaccine Business from Charles River Laboratories International, Inc. (NYSE:CRL). Jan 06
Independent Director recently bought €313k worth of stock Dec 08
Charles River Laboratories International, Inc. Appoints Craig B. Thompson to the Board Dec 08
Charles River Laboratories International, Inc. Launches Endosafe Nexus 200, Emphasizes Critical Importance of Smart Automation for Endotoxin Detection Dec 03
Insider recently sold €117k worth of stock Nov 09
Now 20% undervalued after recent price drop Nov 03 An unknown buyer entered into a definitive agreement to acquire Avian Vaccine Business from Charles River Laboratories International, Inc. (NYSE:CRL) for approximately $200 million.
Charles River Laboratories International, Inc. Launches Hemacare Donor App to Engage Diverse Donors and Source Cell Solutions for Critical Cell and Gene Therapy Research Oct 20
Charles River Laboratories International, Inc. to Report Q3, 2022 Results on Nov 02, 2022 Oct 12
Charles River Launches Naavigation Vector Platform to Accelerate Gene Therapy Programs Oct 11
Investor sentiment improved over the past week Oct 06
Charles River Laboratories International, Inc. Receives Good Manufacturing Practice Certification from European Medicines Agency Aug 10
Second quarter 2022 earnings released: EPS: US$2.15 (vs US$1.76 in 2Q 2021) Aug 04 Charles River Laboratories International, Inc. Revises Revenue Guidance for 2022
Charles River Laboratories International, Inc. to Report Q2, 2022 Results on Aug 03, 2022 Jul 12
First quarter 2022 earnings released: EPS: US$1.84 (vs US$1.23 in 1Q 2021) May 05
Charles River Laboratories International, Inc. Revises Earnings Guidance for 2022 May 05
Charles River Laboratories International, Inc. and Valo Health, Inc. Launch Logica, an Integrated Ai-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets Apr 28
Charles River Laboratories International, Inc. to Report Q1, 2022 Results on May 04, 2022 Apr 14
Charles River Laboratories International, Inc. (NYSE : CRL) acquired Explora BioLabs Holdings, Inc. for approximately $300 million. Apr 07
Charles River Laboratories International, Inc. Announces Management Changes Mar 29
Insider recently sold €102k worth of stock Feb 25
Charles River Laboratories International, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2022 Feb 18
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 17
Charles River Laboratories International, Inc. Provides Earnings Guidance for the Full Year of 2022 Jan 12
Third quarter 2021 earnings released: EPS US$2.05 (vs US$2.07 in 3Q 2020) Nov 04
Chairman recently sold €3.4m worth of stock Aug 11
Charles River Laboratories International, Inc. Increases Earnings Guidance for the Year 2021 Aug 05
Second quarter 2021 earnings released: EPS US$1.76 (vs US$1.36 in 2Q 2020) Aug 05
Charles River Laboratories International, Inc. (NYSE:CRL) completed the acquisition of Vigene Biosciences, Inc.. Jul 01
Charles River Laboratories International, Inc. (NYSE:CRL) signed an agreement to acquire Vigene Biosciences, Inc. for approximately $350 million from Signet Healthcare Partners and others. May 18 Rendimenti per gli azionisti RV6 DE Life Sciences DE Mercato 7D -0.1% 0.1% 0.3% 1Y -17.0% -5.3% 6.9%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: RV6 ha avuto una performance inferiore rispetto al German Life Sciences che ha registrato un rendimento -5.3 % nell'ultimo anno.
Rendimento vs Mercato: RV6 ha avuto una performance inferiore al mercato German che ha registrato un rendimento 6.9 % nell'ultimo anno.
Volatilità dei prezzi Is RV6's price volatile compared to industry and market? RV6 volatility RV6 Average Weekly Movement 7.7% Life Sciences Industry Average Movement 7.0% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.8% 10% least volatile stocks in DE Market 2.4%
Prezzo delle azioni stabile: Il prezzo delle azioni di RV6 è stato volatile negli ultimi 3 mesi.
Volatilità nel tempo: La volatilità settimanale ( 8% ) di RV6 è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni German.
Informazioni sull'azienda Fondato I dipendenti AMMINISTRATORE DELEGATO Sito web 1947 21,100 Jim Foster www.criver.com
Charles River Laboratories International, Inc. fornisce servizi di scoperta di farmaci, sviluppo non clinico e test di sicurezza negli Stati Uniti, in Europa, Canada, Asia e Pacifico e a livello internazionale. Opera attraverso tre segmenti: Modelli e servizi di ricerca (RMS), Scoperta e valutazione della sicurezza (DSA) e Soluzioni di produzione (Manufacturing). Il segmento RMS produce e vende roditori, ratti e topi appositamente allevati per i ricercatori.
Mostra di più Charles River Laboratories International, Inc. Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di Charles River Laboratories International con la sua capitalizzazione di mercato? RV6 statistiche fondamentali Capitalizzazione di mercato €9.15b Guadagni(TTM ) €397.14m Ricavi(TTM ) €3.90b
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) RV6 Conto economico (TTM ) Ricavi US$4.06b Costo del fatturato US$2.61b Profitto lordo US$1.45b Altre spese US$1.04b Guadagni US$413.08m
Ultimi guadagni dichiarati
Sep 28, 2024
Prossima data di guadagno
n/a
Utile per azione (EPS) 8.08 Margine lordo 35.67% Margine di profitto netto 10.17% Rapporto debito/patrimonio netto 60.1%
Come si è comportato RV6 nel lungo periodo?
Vedi performance storica e confronto
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2024/12/30 23:04 Prezzo dell'azione a fine giornata 2024/12/30 00:00 Guadagni 2024/09/28 Guadagni annuali 2023/12/30
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .
Fonti analitiche Charles River Laboratories International, Inc. è coperta da 45 analisti. 17 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione David Toung Argus Research Company Gregory Bolan Avondale Partners Eric Coldwell Baird
Mostra 42 altri analisti 
